Eastwood Bio-Medical Canada Inc (EBM) - Net Assets
Based on the latest financial reports, Eastwood Bio-Medical Canada Inc (EBM) has net assets worth CA$-1.72 Million CAD (≈ $-1.24 Million USD) as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$265.38K ≈ $191.97K USD) and total liabilities (CA$1.98 Million ≈ $1.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Eastwood Bio-Medical Canada Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-1.72 Million |
| % of Total Assets | -646.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -150.8% |
| Growth Volatility | 40.71 |
Eastwood Bio-Medical Canada Inc - Net Assets Trend (2013–2025)
This chart illustrates how Eastwood Bio-Medical Canada Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Eastwood Bio-Medical Canada Inc market capitalisation.
Annual Net Assets for Eastwood Bio-Medical Canada Inc (2013–2025)
The table below shows the annual net assets of Eastwood Bio-Medical Canada Inc from 2013 to 2025. Also explore how fast is Eastwood Bio-Medical Canada Inc growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | CA$-1.63 Million ≈ $-1.18 Million |
-25.66% |
| 2024-10-31 | CA$-1.30 Million ≈ $-937.99K |
-54.22% |
| 2023-10-31 | CA$-840.80K ≈ $-608.22K |
-185.79% |
| 2022-10-31 | CA$-294.20K ≈ $-212.82K |
-103.85% |
| 2021-10-31 | CA$-144.32K ≈ $-104.40K |
-131.42% |
| 2020-10-31 | CA$459.27K ≈ $332.23K |
-64.99% |
| 2019-10-31 | CA$1.31 Million ≈ $948.87K |
-30.56% |
| 2018-10-31 | CA$1.89 Million ≈ $1.37 Million |
-31.61% |
| 2017-10-31 | CA$2.76 Million ≈ $2.00 Million |
-13.88% |
| 2016-10-31 | CA$3.21 Million ≈ $2.32 Million |
-13.92% |
| 2015-10-31 | CA$3.73 Million ≈ $2.70 Million |
-6.53% |
| 2014-10-31 | CA$3.99 Million ≈ $2.88 Million |
+2013.97% |
| 2013-10-31 | CA$-208.29K ≈ $-150.68K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eastwood Bio-Medical Canada Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 611802700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$4.70 Million | % |
| Total Equity | CA$-1.63 Million | 100.00% |
Eastwood Bio-Medical Canada Inc Competitors by Market Cap
The table below lists competitors of Eastwood Bio-Medical Canada Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
$89.56 Million |
|
GrowGeneration Corp
NASDAQ:GRWG
|
$89.56 Million |
|
Collins Co Ltd
TW:2906
|
$89.60 Million |
|
TDG Gold Corp
V:TDG
|
$89.63 Million |
|
Fullerton Technology Co Ltd
TW:6136
|
$89.54 Million |
|
Sam Holdings Corp
VN:SAM
|
$89.50 Million |
|
ÖKOWORLD AG
XETRA:VVV3
|
$89.49 Million |
|
Hf Foods Group Inc
NASDAQ:HFFG
|
$89.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eastwood Bio-Medical Canada Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,296,666 to -1,629,433, a change of -332,767.
- Net loss of 332,767 reduced equity.
- Other factors decreased equity by 0.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-332.77K | -20.42% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Eastwood Bio-Medical Canada Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-10-31 | CA$0.00 | CA$1.80 | x |
| 2014-10-31 | CA$0.08 | CA$1.80 | x |
| 2015-10-31 | CA$0.06 | CA$1.80 | x |
| 2016-10-31 | CA$0.05 | CA$1.80 | x |
| 2017-10-31 | CA$0.04 | CA$1.80 | x |
| 2018-10-31 | CA$0.03 | CA$1.80 | x |
| 2019-10-31 | CA$0.02 | CA$1.80 | x |
| 2020-10-31 | CA$0.01 | CA$1.80 | x |
| 2021-10-31 | CA$0.00 | CA$1.80 | x |
| 2022-10-31 | CA$0.00 | CA$1.80 | x |
| 2023-10-31 | CA$-0.01 | CA$1.80 | x |
| 2024-10-31 | CA$-0.02 | CA$1.80 | x |
| 2025-10-31 | CA$-0.02 | CA$1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eastwood Bio-Medical Canada Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.55%
- • Asset Turnover: 3.57x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-25.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -24.00% | 0.16x | 0.00x | CA$-118.45K |
| 2014 | -13.02% | -112.48% | 0.11x | 1.02x | CA$-917.77K |
| 2015 | -6.99% | -21.95% | 0.31x | 1.03x | CA$-633.01K |
| 2016 | -14.61% | -100.98% | 0.14x | 1.01x | CA$-789.23K |
| 2017 | -17.73% | -102.06% | 0.17x | 1.02x | CA$-765.84K |
| 2018 | -45.63% | -115.86% | 0.33x | 1.19x | CA$-1.05 Million |
| 2019 | -44.19% | -44.84% | 0.78x | 1.26x | CA$-710.85K |
| 2020 | -187.26% | -119.73% | 0.77x | 2.03x | CA$-905.96K |
| 2021 | 0.00% | -62.31% | 1.42x | 0.00x | CA$-596.90K |
| 2022 | 0.00% | -12.35% | 2.22x | 0.00x | CA$-131.16K |
| 2023 | 0.00% | -62.98% | 1.77x | 0.00x | CA$-462.52K |
| 2024 | 0.00% | -64.93% | 2.56x | 0.00x | CA$-326.20K |
| 2025 | 0.00% | -42.55% | 3.57x | 0.00x | CA$-169.82K |
Industry Comparison
This section compares Eastwood Bio-Medical Canada Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $28,873,372
- Average return on equity (ROE) among peers: -107.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eastwood Bio-Medical Canada Inc (EBM) | CA$-1.72 Million | 0.00% | N/A | $89.55 Million |
| Appili Therapeutics Inc (APLI) | $4.42 Million | -97.99% | 0.55x | $1.39 Million |
| Aptose Biosciences Inc (APS) | $3.30 Million | -97.92% | 0.23x | $4.43 Million |
| Arch Biopartners Inc (ARCH) | $-3.88 Million | 0.00% | 0.00x | $43.74 Million |
| Biomind Labs Inc (BMND) | $2.19 Million | -197.55% | 0.15x | $38.72 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $5.11 Million | -84.55% | 0.14x | $410.35 Million |
| Devonian Health Group Inc (GSD) | $4.13 Million | -44.17% | 1.44x | $17.35 Million |
| Helix BioPharma Corp. (HBP) | $6.83 Million | -128.07% | 0.14x | $76.25 Million |
| Hemostemix Inc (HEM) | $573.87K | -268.44% | 0.42x | $9.54 Million |
About Eastwood Bio-Medical Canada Inc
Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appeti… Read more